Tranzyme's TZP-102 Fails Trial
Tranzyme Inc. (Nasdaq: TZYM) reported that its stomach paralysis treatment TZP-102 failed a midstage clinical trial sending the stock price plummeting $3.02 to close at $0.95.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here